The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Overall survival and biomarker analysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.
 
Xinan Sheng
No Relationships to Disclose
 
Xieqiao Yan
No Relationships to Disclose
 
Zhihong Chi
No Relationships to Disclose
 
Lu Si
No Relationships to Disclose
 
Chuanliang Cui
No Relationships to Disclose
 
Bixia Tang
No Relationships to Disclose
 
Siming Li
No Relationships to Disclose
 
Lili Mao
No Relationships to Disclose
 
BIN LIAN
No Relationships to Disclose
 
Xuan Wang
No Relationships to Disclose
 
Xue Bai
No Relationships to Disclose
 
Li Zhou
No Relationships to Disclose
 
Yan Kong
No Relationships to Disclose
 
Jie Dai
No Relationships to Disclose
 
Keith Flaherty
Stock and Other Ownership Interests - Apricity Health; Checkmate Pharmaceuticals; Clovis Oncology; FOGPharma; Fount Therapeutics; Kinnate Biopharma; Loxo; Oncoceutics; PIC Therapeutics; Shattuck Labs; Strata Oncology; Tvardi Therapeutics; X4 Pharma
Consulting or Advisory Role - Adaptimmune; Aeglea Biotherapeutics; Amgen; Array BioPharma; Asana Biosciences; Boston Biomedical; Bristol-Myers Squibb; Cell Medica; Debiopharm Group; FOGPharma; Genentech; Incyte; Lilly; Loxo; Merck; Neon Therapeutics; Novartis; Oncoceutics; Pierre Fabre; Roche; Sanofi; Shattuck Labs; Takeda; Tolero Pharmaceuticals; Tvardi Therapeutics; Verastem
Research Funding - Novartis; Sanofi
Travel, Accommodations, Expenses - Debiopharm Group; Pierre Fabre
 
Jun Guo
Consulting or Advisory Role - Bayer; MSD; Novartis; Oriengene; Pfizer; Roche; Shanghai Junshi BioSciences; Simcere